The level of serum IL-17A was found to be significantly reduced following 12 weeks of treatment, without significant changes in the levels of IL-2, IL-4, IFN-γ and TNF-α in SLE patients under therapy (Fig 4). Here, IL17A is linked to systemic lupus erythematosus.